Clinical Evidence Requirements for Non-IVD Medical Device Registration in Ethiopia

1. Key takeaways

Chapter 4 of the Ethiopian non-IVD dossier is devoted entirely to clinical evidence and contains the following items: the overall clinical evidence summary (4.1), the clinical evaluation report (4.1.1), device-specific clinical trials (4.1.2), the review of clinical literature and other reasonably known information (4.2.3), the informed consent form approved by the ethics committee (4.3) and the contact information of the investigator institutions and the ethics committee (4.4). The clinical evaluation report is the backbone; clinical trials and literature are the two sources of evidence; and the informed consent form and ethics information are accompanying materials required when clinical trials are conducted.

The architecture means that a manufacturer rarely needs local trials to register a device in Ethiopia, but never needs less than a clinical evaluation report. Products supported by literature and foreign market data can satisfy Chapter 4 through a rigorous evaluation report, provided the evidence depth matches the device class. The non-consecutive numbering of the chapter, with 4.2.3 following 4.1, is itself informative: it shows the chapter was consolidated and re-ordered in line with the WHO GBT alignment objective of Version 002, and the current guideline should be followed rather than inferred numbering from older editions.

Two hard boundaries frame the chapter. First, Article 20(4) of Proclamation No. 1112/2019 requires the dossier to be assessed for efficacy or performance, so the clinical chapter carries a statutory obligation, not merely a guideline expectation. Second, Section 7.3 of EFDA-GDL-046 ties the range of evidence to the device class and complexity, which determines how much clinical depth a Class IV device needs compared with a Class I device.

2. Legal basis

3. Expert insights

Insight 1: the non-consecutive chapter numbering, with 4.2.3 appearing after 4.1, indicates that the chapter has undergone consolidation and re-ordering. The numbering of Chapter 4 in Version 002 is not strictly continuous, which is consistent with the revision objective of aligning with the World Health Organization GBT evaluation tool. Manufacturers should organize the chapter according to the actual table of contents of the current guideline and should not infer the numbering from older editions. Preparing the file against the printed headings of Version 002 avoids the embarrassment of a dossier whose internal numbering does not match the guideline the reviewer is holding.

Insight 2: the clinical evaluation report and clinical trials are two layers, not an either-or choice. Section 4.1.1 requires a clinical evaluation report (the evaluative conclusion on all available clinical evidence), while 4.1.2 covers device-specific clinical trials (one source of that evidence). Products that have not conducted local trials must still submit a clinical evaluation report based on literature and foreign data. The report should document the search strategy, the inclusion and exclusion criteria and the appraisal of each source, so that the reviewer can verify that the conclusion rests on identifiable evidence rather than assertion.

Insight 3: the form of clinical evidence for IVDs is different; it is clinical performance, not clinical efficacy. According to the authority’s public statements, Chapter 3 of the IVD dossier requires manufacturers to submit analytical and clinical performance evaluation reports; moreover, a clinical performance study of an IVD is distinguished by definition from the clinical investigation or clinical trial of a general device. IVD manufacturers cannot use the clinical evaluation templates of general devices. The metrics differ too: diagnostic sensitivity and specificity, agreement with a comparative method and inter-laboratory reproducibility replace the endpoint-driven designs of therapeutic device trials.

Insight 4: where human subjects are involved, ethics approval is a hard precondition. Section 4.3 requires the informed consent form approved by the ethics committee (IRB), and 4.4 requires the contact information of the investigator institutions and the ethics committee. These two items apply only when clinical trials are conducted, but once applicable they are mandatory. Sponsors should obtain the approval document before dossier assembly begins, because the review timeline cannot absorb a pending ethics file, and the contact information must be current at the moment of submission.

Insight 5: the depth of evidence is tied to the risk class. The principle established by Section 7.3 is that the range of evidence in the technical documentation increases with the device class, the level of complexity and the extent of adoption of new technologies. For a Class IV device, foreign literature alone is usually insufficient to carry the case, while a Class I device generally does not need clinical trials. Planning the clinical chapter should therefore start from the classification decision: the class determines whether literature review suffices, whether supplementary foreign clinical data are advisable, and whether any local investigation is realistically required.

4. Practical recommendations

1. Determine first whether a local clinical trial is needed: then decide how to compile Chapter 4.
2. Submit a clinical evaluation report regardless of whether a trial is conducted.
3. For IVDs, organize the evidence as a clinical performance study: do not apply general device templates.
4. Where human subjects are involved, obtain ethics committee approval early: and retain the approval documents.
5. Set the depth of evidence according to the risk class: prepare more substantial clinical data for high-risk products.
6. State the evidence sources and the search strategy in the dossier: it facilitates review verification.

5. Verification checklist

• □ The clinical evidence chapter has been compiled according to the Chapter 4 structure
• □ A clinical evaluation report has been submitted (whether or not a trial was conducted)
• □ The evidence sources and the literature search strategy have been stated
• □ For trials conducted, the informed consent form approved by the ethics committee has been submitted
• □ The contact information of the investigator institutions and the ethics committee has been provided
• □ For IVDs, the evidence has been organized as a clinical performance study

Regulatory information verified as of October 29, 2026. The clinical evidence chapter and items listed in this article are based on the current text of Chapter 4 of EFDA/GDL/097 Version 002; when the guideline is revised, they must be re-checked.

• Ethiopia local resource: GRZAN can assist manufacturers from the Chinese mainland and overseas with marketing authorization (MA), Certificate of Competency (CoC) and import licence applications to the Ethiopian Food and Drug Authority (EFDA), including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization application and re-registration, applicability determination for the low-risk notification procedure, Essential Principles conformity justification, labelling and IFU localization (English), and vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.